Apurva Jain
University of Texas MD Anderson Cancer Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Apurva Jain.
Cancer | 2016
Milind Javle; Tanios Bekaii-Saab; Apurva Jain; Ying Wang; Robin Katie Kelley; Kai Wang; Hyunseon C. Kang; Daniel V.T. Catenacci; Siraj M. Ali; Sunil Krishnan; Daniel Ahn; Andrea Grace Bocobo; Mingxin Zuo; Ahmed Kaseb; Vincent A. Miller; Philip J. Stephens; Funda Meric-Bernstam; Rachna T. Shroff; Jeffrey S. Ross
Biliary tract cancers (BTCs) typically present at an advanced stage, and systemic chemotherapy is often of limited benefit.
Cancer | 2016
Daniel H. Ahn; Milind Javle; Chul Ahn; Apurva Jain; Sameh Mikhail; Anne M. Noonan; Christina Wu; Rachna T. Shroff; James L. Chen; Tanios Bekaii-Saab
Biliary tract cancers (BTCs) are uncommon and are associated with a dismal prognosis. Combinations of gemcitabine and platinum chemotherapy (gemcitabine and platinum–based therapy [GP]) form the standard approach for treating advanced BTC. To characterize the spectrum of mutations and to identify potential biomarkers for a GP response in BTC, this study evaluated the genomic landscape and assessed whether mutations affecting DNA repair were associated with GP resistance.
Journal of gastrointestinal oncology | 2016
Humaid O. Al-Shamsi; Deepa Anand; Rachna T. Shroff; Apurva Jain; Mingxin Zuo; Claudius Conrad; Jean Nicolas Vauthey; Milind Javle
BACKGROUND BRCA-associated protein 1, an enzyme encoded by the BAP1 gene, is commonly mutated in uveal melanoma, mesothelioma, and renal cancers. Tumors with BAP1 mutation follow an aggressive course. BAP1 mutations have also been observed in cholangiocarcinoma (CCA). The clinical phenotype of BAP1 mutant CCA may yield useful prognostic and therapeutic information but has not been defined. METHODS The records of CCA patients who underwent next-generation sequencing (NGS) were reviewed, and data on clinical, histopathological, genetic, and radiological features; response to therapy; time to progression; and survival were analyzed. RESULTS Twenty-two cases of BAP1-mutation associated CCA were diagnosed from January 1, 2009, to February 1, 2015, at our center. Twenty patients had intrahepatic CCA and two had extrahepatic CCA. Tumor sizes (largest dimension) ranged from 2 to 16 cm (mean, 8.5 cm). Twelve patients had tumors that were poorly differentiated. Majority of the patients had advanced disease at presentation and 13 had bone metastases. Thirteen patients (59%) experienced rapidly progressive disease following primary therapy (chemotherapy or surgical resection). The mean time to tumor progression was 3.8 months after the first line chemotherapy. CONCLUSIONS BAP1 mutation in CCA may be associated with aggressive disease and poor response to standard therapies. Therefore, BAP1-targeted therapies need to be investigated.
JCO Precision Oncology | 2018
Apurva Jain; Mitesh J. Borad; Ying Wang; Reham Abdel-Wahab; Funda Meric-Bernstam; Keith A. Baggerly; Ahmed Kaseb; Humaid O. Al-Shamsi; Daniel H. Ahn; Thomas DeLeon; Andrea Grace Bocobo; Tanios Bekaii-Saab; Rachna T. Shroff; Milind Javle
PurposeFGFR genetic aberrations (GAs) occur in an estimated 10% to 16% of intrahepatic cholangiocarcinomas (CCAs). The natural history of CCA with FGFR GAs, the prognostic role of coexisting GAs, and the outcome with FGFR-targeted inhibitors are unknown.Patients and MethodsPatients with CCA with FGFR GAs were identified using next-generation sequencing or fluorescence in situ hybridization from four tertiary cancer centers and compared with FGFR wild-type counterparts. Data reviewed included demographic, treatment, overall survival (OS), and GA data. Fisher’s exact test, Kaplan-Meier plots, and log-rank tests were used for statistical analysis.ResultsThree hundred seventy-seven patients with CCA were identified, and 95 had FGFR GAs. FGFR2 GA was most common (n = 74, with 63 fusions) and seen in intrahepatic CCA. In patients with CCA, FGFR GAs occurred more frequently in younger patients (≤ 40 years; 20%) compared with older patients (> 40 years; 6.7%; P < .001), presented at an earlier stage (TNM stage I/...
Oncotarget | 2016
Mingxin Zuo; Asif Rashid; Ying Wang; Apurva Jain; Donghui Li; Anu Behari; Vinay K. Kapoor; Eugene J. Koay; Ping Chang; J. N. Vauthey; Yanan Li; Jaime A. Espinoza; Juan Carlos Roa; Milind Javle
Gallbladder cancer (GBC) is an aggressive malignancy. Although surgical resection may be curable, most patients are diagnosed at an advanced unresectable disease stage. Cholelithiasis is the major risk factor; however the pathogenesis of the disease, from gallstone cholecystitis to cancer, is still not understood. To understand the molecular genetic underpinnings of this cancer and explore novel therapeutic targets for GBC, we examined the key genes and pathways involved in GBC using RNA sequencing. We performed gene expression analysis of 32 cases of surgically-resected GBC along with normal gallbladder tissue controls. We observed that 519 genes were differentially expressed between GBC and normal GB mucosal controls. The liver X receptor (LXR)/retinoid X receptor (RXR) and farnesoid X receptor (FXR) /RXR pathways were the top canonical pathways involved in GBC. Key genes in these pathways, including SERPINB3 and KLK1, were overexpressed in GBC, especially in female GBC patients. Additionally, ApoA1 gene expression suppressed in GBC as compared with normal control tissues. LXR and FXR genes, known to be important in lipid metabolism also function as tumor suppressors and their down regulation appears to be critical for GBC pathogenesis. LXR agonists may have therapeutic value and as potential therapeutic targets.
Journal of Clinical Oncology | 2016
Daniel H. Ahn; Chul Ahn; Apurva Jain; Sameh Mikhail; Christina Wu; Richard M. Goldberg; Kristen K. Ciombor; Anne M. Noonan; Priyanka Sadavartia; Rachna T. Shroff; Milind Javle; James L. Chen; Tanios Bekaii-Saab
287 Background: aBTC is uncommon and has a dismal prognosis with limited therapeutic options. First-line therapy for untreated aBTC is GC, with no approved therapies in the refractory setting. To assess for tumor-specific genetic variants that affect outcomes in patients (pts) who received GC in aBTC, we performed NGS in pts treated with who received GC as first-line therapy. Methods: Archival formalin-fixed, paraffin-embedded samples from pts with mBTC from Ohio State University and MD Anderson Cancer Center who received GC in the first-line and underwent NGS as part of routine care. 315 cancer-related genes plus select introns from 28 genes altered in solid tumors were included in the NGS panel. Univariate Cox regression model was used to determine the association between gene mutations with progression free survival (PFS) and (OS). Results: 80 evaluable pts with aBTC treated with first-line GC chemotherapy underwent successful genomic profiling. A total of 414 cancer-specific mutations were identified,...
Journal of gastrointestinal oncology | 2016
Apurva Jain; Milind Javle
Current Treatment Options in Oncology | 2016
Apurva Jain; Lawrence N Kwong; Milind Javle
Journal of Clinical Oncology | 2017
Milind Javle; Daniel V.T. Catenacci; Apurva Jain; Lauren Young; Kai Wang; Jon Chung; Alexa B. Schrock; Lipika Goyal; Daniel H. Ahn; Shridar Ganesan; Phil Stephens; Vincent A. Miller; Siraj M. Ali; Tanios Bekaii-Saab; Rachna T. Shroff; Jeffrey S. Ross
Journal of Clinical Oncology | 2016
Apurva Jain; Rachna T. Shroff; Ahmed Kaseb; Ying Wang; Reham Abdel-Wahab; Daniel H. Ahn; Andrea Grace Bocobo; Funda Meric-Bernstam; Randi Isaacs; Tanios Bekaii-Saab; Milind Javle